Search Count: 16
 |
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:2.80 Å Release Date: 2018-05-09 Classification: TRANSFERASE/TRANSFERASE Inhibitor Ligands: ZN, F4G |
 |
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:3.36 Å Release Date: 2018-05-09 Classification: Transferase/Transferase Inhibitor Ligands: ZN, F4A |
 |
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:3.60 Å Release Date: 2018-05-09 Classification: TRANSFERASE/TRANSFERASE Inhibitor Ligands: ZN, ET8 |
 |
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:3.38 Å Release Date: 2018-05-09 Classification: TRANSFERASE/TRANSFERASE Inhibitor Ligands: ZN, FYV |
 |
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:3.05 Å Release Date: 2018-05-09 Classification: TRANSFERASE/TRANSFERASE Inhibitor Ligands: ZN, F4J |
 |
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:2.90 Å Release Date: 2018-05-09 Classification: TRANSFERASE/TRANSFERASE Inhibitor Ligands: ZN, F67, CL |
 |
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:3.32 Å Release Date: 2018-05-09 Classification: TRANSFERASE/TRANSFERASE INHIBITOR Ligands: ZN, N45 |
 |
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:2.95 Å Release Date: 2018-05-09 Classification: TRANSFERASE/TRANSFERASE Inhibitor Ligands: ZN, FZJ |
 |
Identification Of Novel Hsp90/Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration Of Potential Utility In Treating Cns Disorders Such As Huntington'S Disease
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:1.82 Å Release Date: 2014-12-24 Classification: CHAPERONE/CHAPERONE INHIBITOR Ligands: 2Q8 |
 |
Identification Of Novel Hsp90/Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration Of Potential Utility In Treating Cns Disorders Such As Huntington'S Disease
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:1.79 Å Release Date: 2014-04-09 Classification: CHAPERONE/CHAPERONE INHIBITOR Ligands: 2Q9 |
 |
Identification Of Novel Hsp90/Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration Of Potential Utility In Treating Cns Disorders Such As Huntington'S Disease
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:1.86 Å Release Date: 2014-04-09 Classification: CHAPERONE/CHAPERONE INHIBITOR Ligands: FGH |
 |
Identification Of Novel Hsp90 / Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration Of Potential Utility In Treating Cns Disorders Such As Huntington S Disease
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:1.96 Å Release Date: 2014-04-09 Classification: CHAPERONE/CHAPERONE INHIBITOR Ligands: 2R6 |
 |
Identification Of Novel Hsp90/Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration Of Potential Utility In Treating Cns Disorders Such As Huntington'S Disease
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:1.93 Å Release Date: 2014-04-09 Classification: CHAPERONE/CHAPERONE INHIBITOR Ligands: 2QA |
 |
Correlation Between Chemotype-Dependent Binding Conformations Of Hsp90 Alpha/Beta And Isoform Selectivity
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:2.77 Å Release Date: 2014-01-22 Classification: CHAPERONE Ligands: 2LC |
 |
Correlation Between Chemotype-Dependent Binding Conformations Of Hsp90 Alpha/Beta And Isoform Selectivity
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:2.00 Å Release Date: 2014-01-15 Classification: CHAPERONE Ligands: E0G, GOL |
 |
Correlation Between Chemotype-Dependent Binding Conformations Of Hsp90 Alpha/Beta And Isoform Selectivity
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:1.65 Å Release Date: 2014-01-15 Classification: CHAPERONE Ligands: 2LC |